Welcome to our dedicated page for Anteris Technologies Global SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Anteris Technologies Global's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Anteris Technologies Global's regulatory disclosures and financial reporting.
Anteris Technologies Global Corp. Chief Financial Officer Matthew McDonnell reported a compensation-related options exercise and associated tax withholding. Through the McDonnell Family Trust, he exercised stock options for 62,001 shares of common stock at exercise prices of $6.32 and $4.84 per share, receiving CHESS Depositary Interests traded on the ASX. Of these, 39,595 shares were delivered to cover tax obligations, a non–open-market disposition. Following these transactions, he holds 27,777 shares directly and 22,406 shares indirectly through the trust.
Anteris Technologies Global Corp. director Susan Elizabeth Knight reported an open-market purchase of the company’s Common Stock. She bought 11,000 shares on June 2, 2026 at a weighted average price of $9.2935 per share, bringing her direct holdings to 11,000 shares.
According to a footnote, the purchase consisted of 5,000 shares at $9.31 per share and 6,000 shares at $9.2797 per share.
Anteris Technologies Global Corp. entered into a Sales Agreement with TD Securities (USA) LLC on May 22, 2026 to sell shares of its common stock in an at-the-market offering with an aggregate offering price of up to $250,000,000 through TD Cowen. This prospectus supplement dated May 26, 2026 updates the Registration Statement and Prospectus related to up to 9,103,796 shares of common stock that may be offered by selling stockholders and attaches the Form 8-K describing the Sales Agreement.
The Sales Agreement permits sales on Nasdaq, negotiated transactions and block trades, and sets TD Cowen’s selling commission at 3.0% of gross proceeds. Net proceeds are intended primarily for development of the DurAVR® Transcatheter Heart Valve System and for working capital and general corporate purposes.
Anteris Technologies Global Corp. entered into a Sales Agreement with TD Securities (USA) LLC (TD Cowen) to establish an at-the-market stock offering program. The company may, at its discretion, sell shares of common stock with an aggregate offering price of up to $250,000,000 through TD Cowen as agent or principal.
Sales can be made over time on Nasdaq or through negotiated block trades, with TD Cowen earning a 3.0% commission on gross proceeds from shares it sells as agent. Anteris currently plans to use any net proceeds primarily to fund development of its DurAVR® Transcatheter Heart Valve System, and the remainder for working capital and general corporate purposes.
Anteris Technologies Global Corp. filed a prospectus supplement establishing an at-the-market offering program to sell up to $250,000,000 of its common stock through TD Securities (USA) LLC (TD Cowen) as sales agent. Sales may occur from time to time on Nasdaq or other trading venues; TD Cowen will receive 3.0% of gross proceeds as compensation.
The supplement uses an example price of $9.00 per share (last reported sale on May 21, 2026) and illustrates issuance of 27,777,777 shares, resulting in up to 125,009,831 shares outstanding under that example. Net proceeds are intended primarily for continued development of the DurAVR® THV System, with remaining amounts for working capital and general corporate purposes.
Anteris Technologies Global Corp. reported that Susan Elizabeth Knight filed an initial ownership statement on Form 3 as a director. The filing does not list any stock or option transactions or current holdings, and serves to formally register her status as an insider with the SEC.
Anteris Technologies Global Corp. director Stephen Denaro filed an initial ownership report showing indirect holdings in the company. The filing lists 23,722 CHESS Depositary Interests in Anteris common stock, held through Australian custodial arrangements and trust structures where Denaro is a beneficiary or is deemed to beneficially own the interests.
Denaro is also reported to hold several indirect stock option positions over Anteris common stock. These include options over 40,000 shares at an exercise price of $9.31 expiring on June 13, 2027, 80,500 shares at $17.35 expiring on September 15, 2028, and 50,000 shares at $16.63 expiring on June 19, 2029, each vesting in three annual installments.
Anteris Technologies Global Corp. files a prospectus supplement to update its shelf prospectus and to register 9,103,796 shares of common stock for resale by the selling stockholders identified in the Prospectus. The supplement attaches the Company’s Form 10-Q and Form 8-K and states the registered shares “may be offered for sale by the selling stockholders” pursuant to the Prospectus.
For context, the number of shares outstanding was 97,342,203 as of May 11, 2026. The supplement amends and supersedes portions of the Prospectus where indicated and should be read together with the Prospectus.
Anteris Technologies Global Corp. ownership update: Nantahala Capital Management, LLC and principals report beneficial ownership of 6,143,154 shares of common stock as of March 31, 2026. The filing states this equals 6.28% of the class and includes 612,244 shares that may be acquired within sixty days through exercise of convertible securities.
The filing is an amended Schedule 13G/A identifying Nantahala as the beneficial owner and Messrs. Wilmot B. Harkey and Daniel Mack as control persons with shared voting and dispositive power over the reported shares.
Anteris Technologies Global Corp. announced that its Board appointed Susan Knight and Stephen Denaro as directors effective May 11, 2026 (May 12, 2026 in Australia). Knight becomes a Class I director with a term running to the 2028 annual meeting and will join the Audit and Risk Committee. Denaro becomes a Class II director with a term running to the 2026 annual meeting. As non-employee directors, they will receive cash retainers and equity compensation under the company’s Non-Employee Director Compensation Policy, including an initial restricted stock unit grant to Knight valued at $250,000, subject to stockholder approval, and potential annual RSU awards valued at $125,000. Denaro also receives an annual fee of AUD $57,645 for serving as company secretary to certain Australian subsidiaries. The company entered into indemnification agreements with both directors, providing protection to the fullest extent permitted under Delaware law.